Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001610520-26-000096
Filing Date
2026-07-31
Accepted
2026-07-31 16:46:29
Documents
1
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5400
  Complete submission text file 0001610520-26-000096.txt   7357
Mailing Address BAHNHOFSTRASSE 45 ZURICH Switzerland CH-8001
Business Address BAHNHOFSTRASSE 45 ZURICH Switzerland CH-8001 41-44-234-1111
UBS Group AG (Filed by) CIK: 0001610520 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6021 National Commercial Banks
(CF Office: 02 Finance)

Mailing Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014
Business Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014 4085018881
REVIVA PHARMACEUTICALS HOLDINGS, INC. (Subject) CIK: 0001742927 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90624 | Film No.: 261229230
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)